###### SUMMARY

1.  **Diagnosis of growth hormone deficiency in adults**

    1.  The insulin tolerance test is recommended as the standard test for diagnosing growth hormone (GH) deficiency (B).

    2.  When GH deficiency is suspected, but an insulin tolerance test is contraindicated, two or more GH stimulation tests (GH-releasing hormone---arginine, glucagon, levodopa, or clonidine stimulation tests) should be administered (B).

    3.  GH deficiency cannot be ruled out even if insulin-like growth factor-1 (IGF-1) levels are normal. However, low serum IGF-1 levels may be indicative of GH deficiency in individuals who do not have a history of poorly controlled diabetes, chronic liver disease, or treatment with oral contraceptives (C).

    4.  GH deficiency can be diagnosed without GH stimulation testing when the typical clinical characteristics of GH deficiency are present, accompanied by deficiencies in three or more pituitary hormones with low serum IGF-1 levels (B).

    5.  Repeated GH stimulation testing should be performed in patients with childhood-onset GH deficiency if they do not have a proven genetic cause of GH deficiency or irreversible damage (B).

    6.  Adult patients with irreversible pituitary damage should not receive repeated GH stimulation tests (B).

2.  **Treatment of growth hormone deficiency in adults**

    1.  Unless contraindicated, GH therapy is recommended for patients with GH deficiency. GH therapy should start from a low dose, considering the patient's age, sex, and estrogen levels (A).

    2.  Clinical improvements, side effects, and targeting serum IGF-1 levels within the age-adjusted reference range should be considered when adjusting the GH dose (A).

    3.  During the adjustment period, IGF-1 levels should be monitored monthly or bimonthly. Once the maintenance level is determined, IGF-1 levels should be monitored around twice per year. Monitoring should include an evaluation of the patient's clinical response, side effects, and IGF-1 levels (B).

3.  **Diagnosis and treatment of growth hormone deficiency in children and adolescents**

    1.  Two or more GH stimulation tests should be administered when GH deficiency is suspected in children (A).

    2.  Repeated GH stimulation tests are not required in GH patients with pituitary lesions or a proven genetic cause of GH deficiency (C).

    3.  GH replacement should be continued in children and adolescents until the epiphyseal plates close or their full height is reached (C).

    4.  GH replacement should be resumed as soon as possible in patients with GH deficiency during transition (B).

4.  **Benefits of growth hormone treatment**

    1.  GH treatment improves body composition, exercise capacity, and bone mineral density in patients with GH deficiency (A).

    2.  GH treatment lowers the risk of cardiovascular disease in patients with GH deficiency, but there is insufficient evidence regarding its effects on mortality reduction (B).

    3.  GH treatment improves quality of life in patients with GH deficiency (A).

5.  **Risks and side effects of growth hormone treatment**

    1.  GH treatment is contraindicated in patients with an active malignancy (except basal cell or squamous cell skin cancers) (A).

    2.  Changes in blood glucose levels should be observed during the course of GH treatment in patients with diabetes mellitus, who may require their antidiabetic medication to be adjusted (B).

    3.  Thyroid and adrenal gland function should be monitored during GH treatment in patients with hypopituitarism (B).

INTRODUCTION
============

Growth hormone (GH) deficiency can be categorized into childhood-onset and adult-onset. Childhood-onset GH deficiency can be further categorized as congenital, acquired, or idiopathic. Adult-onset GH deficiency is generally acquired, although GH deficiency in adults can also occur as a continuation of childhood-onset GH deficiency. The congenital causes are mutations of genes related to GH synthesis and GH receptors and developmental structural disabilities in the brain. The main causes of acquired GH deficiency are tumors in the pituitary gland and hypothalamus, the treatment of such tumors with surgery or radiation, infiltrative diseases, vascular damage, and infections ([Table 1](#t1-enm-2020-35-2-272){ref-type="table"}) \[[@b1-enm-2020-35-2-272],[@b2-enm-2020-35-2-272]\].

The most common cause of adult-onset GH deficiency is hypothalamic-pituitary tumors---either the tumor itself, or surgery or radiation treatment performed to treat the tumor. Although it is rare for pituitary microadenoma to present with hypopituitarism, pituitary macroadenoma presents with at least one pituitary hormone deficiency in approximately 30% to 60% of cases \[[@b3-enm-2020-35-2-272]\]. The main mechanism of hormone deficiency is disruption of circulation due to pressure on the portal veins of the pituitary stalk \[[@b4-enm-2020-35-2-272]\]. Hypopituitarism can also occur after the removal of pituitary tumors, but surgery can lead to a 50% recovery of tumor-induced hypopituitarism \[[@b5-enm-2020-35-2-272]\]. However, GH is the least recovering pituitary hormone \[[@b4-enm-2020-35-2-272]\]. Radiation also induces GH deficiency. The risk of GH deficiency after intracranial radiation is higher in younger patients, and increases with the time after radiation therapy \[[@b6-enm-2020-35-2-272]\]. If the amount of radiation is above 40 Gy, there is a 50% chance of GH deficiency \[[@b7-enm-2020-35-2-272]\].

GH deficiency occurs in 25% of patients with head injury or subarachnoid hemorrhage \[[@b8-enm-2020-35-2-272],[@b9-enm-2020-35-2-272]\]. Some patients recover with time, while others deteriorate; therefore, pituitary hormone levels in these patients should be monitored upon admission and at regular intervals thereafter.

Clinically, patients with GH deficiency report increased body fat, decreased muscle mass, lethargy, and decreased quality of life \[[@b10-enm-2020-35-2-272]\]. However, the presenting symptoms such as fatigue and weakness are nonspecific and common. Therefore, controversy has persisted regarding the correct diagnosis and appropriate treatment of GH deficiency. The Insurance Committee of the Korean Endocrine Society therefore developed a guideline for the diagnosis and treatment of GH deficiency, as cases of GH deficiency increase and some issues arise regarding insurance reimbursements in South Korea.

METHODS USED IN THE DEVELOPMENT OF THIS GUIDELINE
=================================================

This guideline was developed by the Insurance Committee of the Korean Endocrine Society in consultation with the Korean Neuroendocrine Study Group, and the Korean Society of Pediatric Endocrinology. Since there are currently no diagnostic guidelines for GH deficiency and few domestic research has been conducted on this topic, the basis of this guideline was formed by consensus from panel discussion of experts, and the review of existing literature. When evidence was insufficient, recommendations were written according to experts' opinions. When there were differences in opinions, a majority vote was taken. Each recommendation was graded according to the strength of evidence supporting the recommendation, as defined in [Table 2](#t2-enm-2020-35-2-272){ref-type="table"}.

DISCUSSION OF THE RECOMMENDATIONS
=================================

1. Diagnosis of growth hormone deficiency in adults
---------------------------------------------------

GH deficiency is suspected in patients with suggestive clinical presentations (increased body fat, decreased muscle mass, lethargy, and decreased quality of life), and it is diagnosed through GH stimulation tests. An evaluation for GH deficiency should be considered in patients with conditions that can cause GH deficiency, since GH deficiency can be misdiagnosed in patients who only have non-specific clinical symptoms such as lethargy, weakness, and obesity. Before GH secretion is tested, other deficient hormones should be supplemented. Since GH is released in spurts, GH deficiency is diagnosed through GH stimulation tests such as the insulin tolerance test (ITT), the growth hormone-releasing hormone (GHRH), arginine, glucagon, levodopa, and clonidine stimulation tests. There is no single gold-standard test, but the ITT is a major GH stimulation test. The use of GHRH is withdrawn in South Korea as well as in the United States. The basic principle of GH stimulation test is consecutively measuring blood GH levels after an administration of a medication that rapidly stimulates GH. The highest GH level in the samples is then interpreted as the patient's GH response. [Table 3](#t3-enm-2020-35-2-272){ref-type="table"} summarizes the methods, standards, and precautions for GH stimulation tests.

1.  **1.1. The insulin tolerance test is recommended as the standard test for diagnosing GH deficiency.**

2.  **1.2. When GH deficiency is suspected, but an ITT is con-traindicated, two or more GH stimulation tests (GHRH- arginine, glucagon, levodopa, or clonidine stimulation tests) should be administered.**

The ITT is recommended as the standard test for the diagnosis of GH deficiency. ITT has been validated as a standard test for GH deficiency, but it causes hypoglycemia; therefore, it is contraindicated in elderly patients and patients with a history of epilepsy or cardiovascular disease due to its risks \[[@b11-enm-2020-35-2-272]\]. Even healthy individuals should be continuously monitored during ITT. In obese patients with insulin resistance, a greater dose of insulin is injected to induce hypoglycemia, and this process increases the risk of delayed hypoglycemia. ITT is also difficult to replicate, since the response to ITT varies from occasion to occasion in healthy individuals. The response to ITT also depends on the menstrual cycle.

Aimaretti et al. \[[@b12-enm-2020-35-2-272]\] reported that injecting arginine, which suppresses the secretion of hypothalamic somatostatin, together with GHRH served as a potent and safe GH stimulation test. Biller et al. \[[@b13-enm-2020-35-2-272]\] compared five types of GH stimulation tests. In their study, five stimulation tests were administered in random order to 39 patients with panhypopituitarism, 21 patients with either isolated GH deficiency or no more than one additional pituitary hormone deficiency, and 34 healthy controls matched by age, sex, and body mass index (BMI). At a GH level of 5.1 μg/L, ITT had 96% sensitivity and 92% specificity, and the GHRH-arginine test had a similar diagnostic validity at a GH level of 4.1 μg/L, with 95% sensitivity and 91% specificity. GHRH, however, stimulates the pituitary gland directly and may result in false negatives in patients with disorders in the hypothalamus or a history of radiation treatment. The GH level for the GHRH-arginine test needs to be adjusted in patients who are older or have a higher BMI \[[@b14-enm-2020-35-2-272],[@b15-enm-2020-35-2-272]\]. A higher BMI also leads to a slightly lower GH response in ITT, but it is not recommended to adjust the GH levels for the diagnostic cut-point \[[@b16-enm-2020-35-2-272]\]. For tests using arginine alone, a GH level of 0.4 μg/L was identified as a suitable cut-point; however, this low value compromises diagnostic accuracy, and this test is therefore not recommended.

Glucagon indirectly stimulates GH by stimulating insulin secretion; since the GH response is delayed, the glucagon stimulation test requires a minimum of 3 hours to complete and poses a risk of delayed hypoglycemia. For this test, intramuscular or subcutaneous injection is more effective than intravenous injection. The GH level for diagnosis is adequate at 3 μg/L, while in patients with obesity (BMI \>25 kg/m^2^) whose GH response is less sensitive, the GH level for diagnosis is 1 μg/L \[[@b17-enm-2020-35-2-272]--[@b21-enm-2020-35-2-272]\]. Although higher blood glucose levels are associated with a weaker GH response, specific GH levels for diagnosis according to blood glucose levels have not been determined yet \[[@b22-enm-2020-35-2-272]\]. Side effects include nausea, vomiting, and headaches; furthermore, severe hypotension, hypoglycemia, and convulsions have been reported in the elderly.

Levodopa stimulates GH through dopamine receptors in the hypothalamus, and clonidine through releasing GHRH via alpha receptors. Levodopa and clonidine are weak GH stimulators, so a diagnosis is possible when a sensitive method of GH measurement is used. There are lack of data regarding the optimal GH cut-off values according to age, sex, BMI, blood glucose levels, or the presence of any underlying disorders.

Macimorelin, an oral GH secretagogue receptor-1a agonist that was recently approved in the United States and Europe, stimulates GH release with similar sensitivity (92%) and specificity (96%) to ITT, and has fewer side effects \[[@b23-enm-2020-35-2-272]\]. A common side effect is a slight disturbance in taste that improves with time, although a severe side effect reported was long QT interval on electrocardiography. Macimorelin is not yet introduced in South Korea.

The analytical method of determining GH levels has a major impact on the GH cut-off value for the diagnosis of GH deficiency. Thus, it is important to ensure that accurate measurements of GH are applied. However, GH in blood samples is made up of diverse isoforms and isomers, of which the 22 and 20 kDa forms are the most common. Furthermore, GH binding proteins can bind up to 50% of GH in the blood, which can interfere with the immunoassay of GH. Moreover, institutions measure GH in different ways. This variation in GH measurement underscores the importance of using the GH calibration standard 98 of 574 of the National Institute for Biological Standards and Control and using highly purified recombinant pituitary GH \[[@b24-enm-2020-35-2-272]\]. All manufacturers of measurement equipment should specify the validity of the assays, the GH isoforms measured, the analytes, the antibodies used, and whether GH binding proteins interfere with the measurements.

1.  **1.3. GH deficiency cannot be ruled out even if IGF-1 levels are normal. However, low serum IGF-1 levels may be indicative of GH deficiency in individuals who do not have a history of poorly controlled diabetes, chronic liver disease, or treatment with oral contracep-tives.**

2.  **1.4. GH deficiency can be diagnosed without GH stimu-lation testing when the typical clinical characteristics of GH deficiency are present, accompanied by deficien-cies in three or more pituitary hormones with low se-rum IGF-1 levels.**

GH deficiency cannot be ruled out even when serum IGF-1 levels are normal \[[@b13-enm-2020-35-2-272],[@b25-enm-2020-35-2-272]--[@b27-enm-2020-35-2-272]\]. Higher BMIs are associated with a weaker GH response and increased IGF-1 levels \[[@b28-enm-2020-35-2-272]\]. However, if a patient with a high BMI has a low IGF-1 level, it can be considered as GH deficiency.

GH stimulation tests can be omitted if there are abnormally low levels of three or more pituitary hormones and IGF-1 levels are low (at least 2.0 standard deviations lower than normal), if the patient has a structural hypothalamic-pituitary condition, if the patient has a genetic condition that impacts the hypothalamic-pituitary axis, and if there is a structural lesion in the hypothalamus or pituitary gland \[[@b1-enm-2020-35-2-272],[@b25-enm-2020-35-2-272],[@b29-enm-2020-35-2-272]\].

1.  **1.5. Repeated GH stimulation testing should be per-formed in patients with childhood-onset GH deficiency if they do not have a proven genetic cause of GH defi-ciency or irreversible damage.**

2.  **1.6. Adult patients with irreversible pituitary damage should not regularly receive repeated GH stimulation tests.**

When patients with idiopathic child-onset GH deficiency are re-evaluated in adulthood, most show normal GH secretion \[[@b30-enm-2020-35-2-272]\]. However, GH deficiency due to structural conditions, including tumors, surgery, radiation, and genetic disorders, do not improve in adulthood, so GH stimulation tests is not needed to be repeated in such patients \[[@b31-enm-2020-35-2-272]\] .

2. Treatment of growth hormone deficiency in adults
---------------------------------------------------

1.  **2.1. Unless contraindicated, GH therapy is recommended for patients with GH deficiency. GH therapy should start from a low dose, considering the patient's age, sex, and estrogen levels.**

2.  **2.2. Clinical improvements, side effects, and targeting se-rum IGF-1 levels within the age-adjusted reference range should be considered when adjusting the GH dose.**

Unless contraindicated, GH replacement therapy is recommended for patients with GH deficiency diagnosed through GH stimulation tests. Patients should be started on low doses, since side effects are dose-dependent \[[@b32-enm-2020-35-2-272]\]. Common side effects include fluid retention, arthralgia, muscle pain, sensory disturbances, carpal tunnel syndrome, sleep apnea, sleep disorders, and dyspnea. Most of these side effects occur in around 20% of patients, in a dose-dependent manner. Side effects are more frequent in elderly, obese, and female patients, but subside after the dose is lowered \[[@b33-enm-2020-35-2-272]\]. The GH doses for adults were initially extrapolated based on body weight from dose recommendations for children. However, shifting from weight-based to individualized dose recommendations reduces side effects by half \[[@b34-enm-2020-35-2-272]\].

GH secretion decreases with age, and the side effects of GH are more common in elderly patients. Therefore, the appropriate therapeutic levels of GH are lower in elderly individuals and higher in younger individuals \[[@b35-enm-2020-35-2-272]\]. For individuals between the ages of 30 to 60, a suitable starting dose is 0.2 to 0.3 mg/day (0.8 to 1.2 IU/day). For those below the age of 30, a higher dose of 0.4 to 0.5 mg/day (1.6 to 2.0 IU/day) is possible, while in individuals above the age of 60, the starting dose should be 0.1 to 0.2 mg/day (0.4 to 0.8 IU/day) and increased slowly thereafter ([Fig. 1](#f1-enm-2020-35-2-272){ref-type="fig"}). The dosage should be increased by 0.1 to 0.2 mg/day (0.4 to 0.8 IU/day) monthly or bimonthly, and the maintenance level should be determined based on an evaluation of the patient's clinical response, side effects, and the normal range of IGF-1 levels for the patient's age group \[[@b1-enm-2020-35-2-272]\]. Although a normal IGF-1 level is targeted, the evidence remains unclear. Clinical responses can usually be observed after 6 months of treatment.

Females generally show higher GH resistance, and therefore require higher starting and maintenance doses \[[@b36-enm-2020-35-2-272]\]. Estrogen stimulates suppressor of cytokine signaling 2 (SOCS2), a specific non-competitive suppressor of GH in the liver \[[@b37-enm-2020-35-2-272]\], where 85% of serum IGF-1 originates. Since oral estrogen suppresses IGF-1, a higher dose of GH is required to maintain the same IGF-1 levels in females \[[@b37-enm-2020-35-2-272]\]. Even at the same IGF-1 levels, GH has less effect on body fat, low-density lipoprotein cholesterol, and bone turnover markers in females \[[@b38-enm-2020-35-2-272]\]. When oral estrogen is changed to transdermal estrogen, GH requirement is reduced \[[@b39-enm-2020-35-2-272]\].

1.  **2.3. During the adjustment period, IGF-1 levels should be monitored monthly or bimonthly. Once the mainte-nance level is determined, IGF-1 levels should be moni-tored around twice per year. monitoring should include an evaluation of the patient's clinical response, side ef-fects, and IGF-1 levels.**

During the adjustment period, Adequacy of GH dose including an evaluation of the patient's clinical response, side effects, and IGF-I levels \[[@b1-enm-2020-35-2-272]\] should be monitored monthly or bimonthly. Once the maintenance level is determined, IGF-1 levels should be monitored every six months ([Fig. 1](#f1-enm-2020-35-2-272){ref-type="fig"}). The blood levels of lipid and fasting glucose should be tested every year, and if the initial bone mineral density is abnormal, bone mineral density should be re-evaluated every 1.5 to 2 years. Additionally, waist circumference and quality of life should be evaluated. If the patient is already taking thyroid or adrenal hormones, their doses should be adjusted after GH is introduced. These recommendations are based on empirical experience. Although it is unclear precisely how long GH should be administered, if there is no clear response to GH replacement after at least 1 year, treatment can be suspended \[[@b1-enm-2020-35-2-272]\].

The recently developed long-acting GH is formulated to be taken once a week or once a month instead of daily. Long-acting GH may be more effective because it reduces the inconvenience and discomfort of daily GH injections, thereby increasing compliance. A recently published meta-analysis reported long-acting GH and daily GH to have similar efficacy and safety profiles \[[@b40-enm-2020-35-2-272]\]. However, IGF-1 levels were significantly elevated in children with GH deficiency who received long-acting GH. Thus, additional research on long-acting GH should investigate how the peak and trough levels of GH and IGF-1 influence efficacy and safety, how the dose should be adjusted, when IGF-1 levels should be monitored, and how to compare long-term cost-effectiveness between daily and long-acting GH preparations \[[@b41-enm-2020-35-2-272]\].

3. Diagnosis and treatment of growth hormone deficiency in children and adolescents
-----------------------------------------------------------------------------------

1.  **3.1. Two or more GH stimulation tests should be admin-istered when GH deficiency is suspected in children.**

Childhood onset GH deficiency may be a long lasting endocrine conditions, starting in childhood and continuing into adulthood. Diagnostic workup of childhood onset GH deficiency include auxology, bone age view, measurement of IGF-1 and IGF binding protein 3, GH stimulation tests, brain imaging and, genetic tests if needed \[[@b42-enm-2020-35-2-272]\]. GH stimulation test is one of the most important diagnostic tools, but it is also intrusive and is accompanied by a risk of side effects \[[@b43-enm-2020-35-2-272]\]. The validity and reproducibility of GH stimulation tests have also been called into question \[[@b44-enm-2020-35-2-272],[@b45-enm-2020-35-2-272]\]. Therefore, to diagnose GH deficiency, two or more GH stimulation tests should be administered. Children diagnosed with GH deficiency should receive GH replacement six to seven times a week, at 22 to 35 μg/kg/day (0.16 to 0.24 mg/kg/week) or 12 IU (4 mg) per body surface area (m^2^)/week by subcutaneous injection until their epiphyseal plates close \[[@b46-enm-2020-35-2-272]\].

1.  **3.2. Repeated GH stimulation tests are not required in GH patients with pituitary lesions or a proven genetic cause of GH deficiency.**

Controversy exists regarding the management in the transition period of adolescence of children or adolescents with GH deficiency. If a patient requires ongoing GH therapy, GH stimulation tests should be re-administered to reevaluate the function of the hypothalamic-pituitary axis. However, in patients with a high probability of irreversible GH deficiency, re-evaluation of GH status is not necessary \[[@b25-enm-2020-35-2-272]\]. Patients with structural lesions in the hypothalamus or pituitary gland or other structural problems, such as tumors, have a high risk of persistent GH deficiency \[[@b47-enm-2020-35-2-272],[@b48-enm-2020-35-2-272]\]. Several genetic defects may also lead to an irreversible GH deficiency \[[@b49-enm-2020-35-2-272]\]. Therefore, GH stimulation tests is not need to be repeated in patients with definite genetic or structural pituitary abnormalities.

1.  **3.3. GH replacement should be continued in children and adolescents until the epiphyseal plates close or their full height is reached.**

The benefits of GH replacement during the transition period of adolescence are widely recognized. Childhood-onset GH deficiency contributes to low bone mass and an increased risk of fracture in adulthood \[[@b50-enm-2020-35-2-272]\]. It also results in developmental bone mass deficits both at the time of diagnosis and final height \[[@b51-enm-2020-35-2-272]\]. In a previous study, when GH replacement was resumed, body composition improved, with a 14% increase in muscle mass and a 7% decrease in body fat over a 2-year period \[[@b35-enm-2020-35-2-272]\]. Some studies have reported deterioration in dyslipidemia after suspension of GH replacement in patients with childhood-onset GH deficiency \[[@b52-enm-2020-35-2-272]\]. Other studies have reported a reduction in cardiac dimensions after suspension of GH therapy during this transition period \[[@b53-enm-2020-35-2-272]\]. Therefore, GH replacement should be maintained until either the epiphyseal plates close or the final height is reached, since there are various benefits besides height gain.

1.  **3.4. GH replacement should be resumed as soon as possi-ble in patients with GH deficiency during adolescence.**

It is widely known that appropriate GH replacement during the transition period of adolescence is necessary \[[@b54-enm-2020-35-2-272]\]. The purpose of GH replacement during this transition period is to maintain the continuity of hormonal care and to prevent health problems. Several studies have reported a risk of dropout among patients with GH deficiency who did not receive GH replacement during this transition period \[[@b54-enm-2020-35-2-272]\]. In one study, 21% of patients in puberty discontinued GH treatment without a comprehensive evaluation, and among those patients, 18% were lost to follow-up \[[@b55-enm-2020-35-2-272]\]. Thus, strategies for successful transition including standardized referral systems should be established \[[@b56-enm-2020-35-2-272]\]. If GH replacement is discontinued in such patients, it should be resumed as soon as possible.

4. Benefits of growth hormone treatment
---------------------------------------

1.  **4.1. GH treatment improves body composition, exercise capacity, and bone mineral density in patients with GH deficiency.**

GH deficiency can cause decreased bone mineral density, muscle strength, and exercise capacity, deterioration in memory, decreased physical activity and vitality, lethargy, difficulty in concentration, and sleep disorders \[[@b57-enm-2020-35-2-272],[@b58-enm-2020-35-2-272]\]. Patients also are exposed to a high risk of cardiovascular disease due to central obesity, dyslipidemia, or insulin resistance \[[@b59-enm-2020-35-2-272]--[@b61-enm-2020-35-2-272]\].

Several studies consistently reported that GH treatment had the significant effect on body composition including decrease in fat mass and increase in muscle mass \[[@b62-enm-2020-35-2-272],[@b63-enm-2020-35-2-272]\]. It was further reported that GH replacement led to a decrease preferentially in visceral fat \[[@b64-enm-2020-35-2-272]\] and an increase in lean body mass \[[@b27-enm-2020-35-2-272],[@b65-enm-2020-35-2-272]\], and improvements in muscle function \[[@b65-enm-2020-35-2-272]\] and lipid metabolism \[[@b66-enm-2020-35-2-272]\] can be expected as well. Studies in South Korea confirmed the tendency for GH treatment to achieve reductions in weight, body fat, and insulin resistance \[[@b67-enm-2020-35-2-272]--[@b70-enm-2020-35-2-272]\].

Published data have shown that bone mineral density in adults with GH deficiency is lower than the age- and sex-matched healthy controls \[[@b71-enm-2020-35-2-272]--[@b73-enm-2020-35-2-272]\]. Moreover, the severity of bone loss is correlated to the severity of GH deficiency \[[@b74-enm-2020-35-2-272]\]. Accordingly, the fracture risk in GH deficiency patients is 2- to 5-fold higher than in healthy controls \[[@b75-enm-2020-35-2-272],[@b76-enm-2020-35-2-272]\]. Significant improvements in bone mineral density in response to GH treatment were reported among males and patients with severe bone loss \[[@b77-enm-2020-35-2-272]\]. Even in patients without a history of osteoporosis, GH treatment prevented fractures \[[@b78-enm-2020-35-2-272]\].

1.  **4.2. GH treatment lowers the risk of cardiovascular disease in patients with GH deficiency, but there is insufficient evidence regarding its effects on mortality reduction.**

Previous studies have shown that GH deficiency increases the risk of cardiovascular disease via its negative effects on metabolic parameters, such as abdominal obesity, insulin resistance, and deterioration of lipid panels, and increases in various inflammatory markers \[[@b79-enm-2020-35-2-272]\]. GH deficiency has also been reported to negatively influence heart function and atherosclerosis by causing reduced thickness of the left ventricle, impairment of ejection fraction, and diastolic filling in the left ventricle \[[@b80-enm-2020-35-2-272]\]. A previous study reported that the cardiovascular mortality rate was twice as high in adult patients with GH deficiency than in their counterparts without GH deficiency \[[@b81-enm-2020-35-2-272]\]. Svensson et al. \[[@b82-enm-2020-35-2-272]\] reported that in patients with hypopituitarism, GH replacement led to lower rates of fatal myocardial infarction and a lower mortality rate \[[@b83-enm-2020-35-2-272]\]. A meta-analysis also found that GH replacement reduced the mortality rate among male patients with hypopituitarism \[[@b84-enm-2020-35-2-272]\], and a domestic study reported a reduction in markers of inflammation through GH replacement \[[@b70-enm-2020-35-2-272]\]. GH replacement can be expected to have a positive effect on cardiovascular disease. However, the mortality improvement is lower for women than for men \[[@b80-enm-2020-35-2-272]\], and the question of whether GH replacement can fully restore the long-term negative effects of GH deficiency on cardiovascular risk factors remains \[[@b83-enm-2020-35-2-272]\]. Therefore, it is still difficult to draw a definite conclusion on GH replacement and improvements in cardiovascular mortality, and additional longitudinal, large-scale research is required \[[@b85-enm-2020-35-2-272]\].

1.  **4.3. GH treatment improves quality of life in patients with GH deficiency.**

Patients with GH deficiency may experience an impaired quality of life due to the deterioration in metabolic parameters and physical capacity, as well as because of their increased cardiovascular risk. Studies measuring the quality of life among adult patients diagnosed with GH deficiency using various tools in comparison to that of healthy adults found significantly poorer results for sleep, social integration, and physical activity among patients with GH deficiency, and their physical health negatively influenced their occupational status and daily life \[[@b86-enm-2020-35-2-272]\]. It was found by Svensson et al. \[[@b82-enm-2020-35-2-272]\] that GH replacement improved quality of life, and a domestic study also reported improvements in quality of life through increase of bone mineral density, lean body mass, and muscular strength, and decrease of body fat among healthy Korean women aged 60 or above after 6 months of GH replacement \[[@b87-enm-2020-35-2-272],[@b88-enm-2020-35-2-272]\].

5. Risks and side effects of growth hormone treatment
-----------------------------------------------------

The most common side effects of GH treatment are peripheral edema, joint pain, carpal tunnel syndrome, sensory disturbances, and increased blood glucose levels \[[@b33-enm-2020-35-2-272],[@b89-enm-2020-35-2-272]\]. Side effects are more prevalent in elderly or obese patients and those who have been overtreated with GH \[[@b33-enm-2020-35-2-272]\]. The side effects of GH treatment can last for 3 or more years \[[@b90-enm-2020-35-2-272]\]. In particular, the possibility that GH replacement may cause malignant conditions to worsen should be carefully considered in the management of hypopituitarism.

1.  **5.1. GH treatment is contraindicated in patients with an active malignancy (other than basal cell or squamous cell skin cancers).**

Theoretically, the increased activity of the IGF-1 axis resulting from GH treatment can exacerbate malignant tumors, as GH and increased IGF-1 levels are independently associated with the development of various malignant tumors \[[@b91-enm-2020-35-2-272]\]. Therefore, GH treatment is contraindicated in patients with malignancies. This recommendation is based on the theoretical possibility that GH treatment could increase the size of existing tumors, but there is not yet any concrete support for this proposal from clinical research \[[@b92-enm-2020-35-2-272]\]. Inpatients with GH deficiency, research on the risk of GH treatment-related recurrence of malignant tumors or secondary tumor formation has mostly been conducted among childhood cancer patients who had received GH treatment \[[@b93-enm-2020-35-2-272]--[@b95-enm-2020-35-2-272]\]. Although some studies reported a slight increase in the risk of secondary tumor formation among childhood cancer patients who had previously received GH treatment \[[@b94-enm-2020-35-2-272],[@b95-enm-2020-35-2-272]\], most studies found no association between GH treatment and the recurrence of malignant tumors or secondary tumor formation \[[@b96-enm-2020-35-2-272]--[@b103-enm-2020-35-2-272]\]. These results indicate that if an intracranial residual benign tumor is stable over a long period, there is no need to prohibit GH treatment. GH treatment can be administered to patients with a history of malignancy if they have been in remission for at least 1 year without recurrence \[[@b104-enm-2020-35-2-272]\].

1.  **5.2. Changes in blood glucose levels should be observed during the course of GH treatment in patients with di-abetes mellitus, who may require their antidiabetic medication to be adjusted.**

GH and IGF-1 independently influence insulin resistance and insulin secretion by pancreatic β-cells \[[@b105-enm-2020-35-2-272]\]. Both increased and decreased GH and IGF-1 levels can cause abnormalities in blood glucose levels. The elevated blood glucose levels present in patients with acromegaly and the increased insulin resistance in patients with GH deficiency are clinically observed. Large-scale clinical studies have reported GH treatment is related to insulin resistance and type 2 diabetes \[[@b106-enm-2020-35-2-272]\]. Insulin sensitivity following GH treatment varies since abnormlities in blood glucose levels depend on body composition, age, and genetic characteristics. According to a randomized controlled trial conducted by Hoffman et al. \[[@b27-enm-2020-35-2-272]\], compared to the placebo group, the group that received GH treatment had a statistically significant 13% increase in prediabetes and a 4% increase in diabetes. Therefore, when GH treatment is given, careful follow-up on diabetes is necessary, and adjustments to anti-diabetic medication should be considered.

1.  **5.3. Thyroid and adrenal gland function should be mon-itored during GH treatment in patients with hypopitu-itarism.**

It is common for patients with GH deficiency to have other manifestations of hypopituitarism, and thyroid and adrenal gland function---even if they are initially normal---should be monitored during GH treatment \[[@b58-enm-2020-35-2-272]\]. Hypothyroidism is accompanied by reduced secretion of IGF-1 and GH \[[@b107-enm-2020-35-2-272],[@b108-enm-2020-35-2-272]\]. Therefore, in order to evaluate GH function accurately, central hypothyroidism should be treated first. During treatment, thyroid function must be evaluated, since GH treatment can reduce free thyroxine levels. Among patients with GH deficiency, 36% to 47% of those with normal thyroid function became hypothyroid and 16% to 18% of those with hypothyroidism required an increase in levothyroxine dose within 3 to 6 months of GH treatment \[[@b109-enm-2020-35-2-272],[@b110-enm-2020-35-2-272]\]. When GH treatment is started or the dose is changed, central hypothyroidism should be checked after 6 weeks \[[@b111-enm-2020-35-2-272]\].

In addition, hypothalamic-pituitary-adrenal function should be evaluated before and after GH treatment. Since GH suppresses the enzyme 11 β-hydroxysteroid dehydrogenase type 1 converting cortisone to cortisol, the ratio of cortisone to cortisol is higher in patients with GH deficiency \[[@b108-enm-2020-35-2-272],[@b112-enm-2020-35-2-272]\]. Therefore, even if adrenal insufficiency is present, it might not be diagnosed if accompanied by GH deficiency. When GH is given to such patients, possible adrenal function deterioration should be carefully considered \[[@b113-enm-2020-35-2-272],[@b114-enm-2020-35-2-272]\].

CONCLUSIONS
===========

Although it remains controversial whether GH treatment reduces cardiovascular mortality in patients with hypopituitarism, GH treatment in patients with GH deficiency has more benefits than harm. It is important to accurately diagnose GH deficiency through GH stimulation tests before starting GH treatment. The GH dose should be individualized to minimize side effects and to maximize clinical efficacy. Side effects and clinical response should be monitored regularly while patients are treated with  the maintenance dose.
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###### 

Cause of Growth Hormone Deficiency

  Congenital                                                              Acquired
  ----------------------------------------------------------------------- --------------------------------------------------
  Genetic                                                                 Neoplastic
   Transcription factor defects (PIT-1, PROP-1, LHX3/4, HESX-1, PITX-2)    Pituitary adenoma
   GHRH receptor gene defects                                              Craniopharyngioma
   GH secretagogue receptor gene defects                                   Rathke's cleft cyst
   GH gene defects                                                         Glioma/astrocytoma
   GH receptor/post receptor defects                                       Germinoma
                                                                          
  Associated with brain structural defects                                 Metastatic
                                                                          
   Agenesis of corpus callosum                                            Infiltrative/granulomatous disease
   Septo-optic dysplasia                                                   Langerhans cell histiocytosis
   Empty sella syndrome                                                    Sarcoidosis
   Holoprosencephaly                                                       Hypophysitis
                                                                          
   Encephalocele                                                          Vascular damage
   Hydrocephalus                                                           Head injury
   Arachnoid cyst                                                          Pituitary tumor apoplexy
                                                                          
  Associated with midline facial defects                                   Sheehan's syndrome
   Single central incisor                                                  Subarachnoid hemorrhage
                                                                          
   Cleft lip/palate                                                       Treatment of pituitary and hypothalamic diseases
                                                                           Cranial irradiation
                                                                           Surgery of the pituitary or hypothalamus
                                                                          
                                                                          Central nervous system infection
                                                                           Idiopathic

Modified from Molitch et al. \[[@b1-enm-2020-35-2-272]\]; and Melmed \[[@b2-enm-2020-35-2-272]\], with permission from Massachusetts Medical Society.

PIT-1, pituitary transcription factor-1; PROP-1, prophet of pit-1; LHX3/4, LIM class homeobox transcription factor Lhx3, 4; HESX-1, homeobox-1; PITX-2, paired-like homeodomain transcription factor-2; GHRH, growth hormone-releasing hormone; GH, growth hormone.

###### 

Definition of Recommendation Levels

  Recommendation level   Definition
  ---------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  A                      When there is a clear rationale for the recommendations: When manifold randomized controlled trials that can be generalized because they have sufficient test or meta-analysis results support a recommendation.
  B                      When there is a reliable basis for the recommendations: When reasonable grounds support this through well-performed cohort studies or patient---control group studies.
  C                      When there is a possible basis for the recommendations: When relevant grounds are seen through randomized clinical studies or case reports and observational studies carried out in a small institution, despite their inherent unreliability.
  E                      Expert recommendations: There is no basis to support the recommendations, but they are supported by expert opinion or expert clinical experience.

###### 

Dynamic Tests for Diagnosing GH deficiency

  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Hormone test    Procedure                                                                                                    GH cut-points, μg/L                                                Consideration
  --------------- ------------------------------------------------------------------------------------------------------------ ------------------------------------------------------------------ -------------------------------------------------------------------------------------------------------------------------------------------------
  ITT             Administer insulin, 0.05--0.15 U/kg iv\                                                                      \>5.0 (AACE, 2019)\                                                Glucose should drop \<40 mg/dL\
                  Sample blood at −30, 0, 30, 60, 120 min for GH and glucose                                                   \>3--5 (ES, 2016)                                                  Contraindication: a history of seizures, coronary artery disease, pregnancy, or age \>65 yr

  GHRH-arginine   Administer GHRH, 1 μg/kg (max 100 μg) iv followed by an arginine infusion 0.5 g/kg (max 35 g) over 30 min\   \>4 μg/L but cutoffs for GH response should be correlated to BMI   Can give false normal GH response if GHD is due to hypothalamic damage
                  Sample blood at 0, 30, 45, 60, 75, 90, 105, and 120 min for GH                                                                                                                  

  Glucagon        Administer glucagon, 1 mg (1.5 mg if weight \>90 kg) im\                                                     \>3 μg/L (if BMI ≥25 kg/m^2^, \>1 μg/L)                            Obesity may blunt GH response to stimulation\
                  Sample blood at 0, 30, 60, 90, 120, 150, 180, 210, and 240 min for GH and glucose                                                                                               Contraindication: severe fasting hyperglycemia \>180 mg/dL\
                                                                                                                                                                                                  Nausea, vomiting, headache, and delayed hypoglycemia may occur

  Levodopa        Administer Levodopa 500 mg po\                                                                               \>3 μg/L                                                           Nausea, vomiting, dizziness, and headache may occur
                  Sample blood at 0, 60, 90, and 120 min for GH                                                                                                                                   

  Clonidine       Administer clonidine, 0.15 mg/m^2^ (max 0.25 mg) po\                                                         \>3 μg/L                                                           Hypotension and drowsiness may occur\
                  Sample blood at 0, 30, 60, 90, and 120 min for GH                                                                                                                               Contraindication: a history of coronary artery disease

  Macimorelin     Administer 0.5 mg/kg, oral solution                                                                          \>2.8 μg/L                                                         Avoid concomitant use with drugs known to prolong QT interval; hypothalamic disease may not be accurately diagnosed side effect: mild dysgeusia
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

GH, growth hormone; ITT, insulin-tolerance test; iv, intravenous; AACE, American Association of Clinical Endocrinologists; ES, Endocrine Society; GHRH, growth hormone-releasing hormone; BMI, body mass index; GHD, growth hormone deficiency; im, intramuscular; po, *per os*.
